Context Therapeutics (CNTX) Stock Chart & Stock Price History $0.63 +0.01 (+2.21%) As of 12:58 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Context Therapeutics Stock Price Performance The Context Therapeutics (CNTX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 68.63%, with a year-to-date return of -40.24%. In the past month, the stock has decreased 19.54%, reflecting recent market activity. As of the latest close, Context Therapeutics traded at $0.62 with a market cap of $55.64 million and volume of 1.49 million shares. Receive CNTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-5.51%1 Month Performance-19.54%3 Month Performance-9.06%Year-To-Date Performance-40.24%1 Year Performance-68.63% CNTX Stock Chart for Thursday, June, 12, 2025 CNTX Chart by TradingView Context Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/11/2025$0.67$0.62-7.21%$0.72$0.601.49 million shs$55.64 million06/10/2025$0.70$0.67-4.89%$0.80$0.65417,317 shs$59.97 million06/09/2025$0.66$0.70+5.84%$0.84$0.661.11 million shs$63.05 million06/06/2025$0.55$0.66+20.40%$0.70$0.55400,339 shs$59.57 million06/05/2025$0.58$0.55-4.12%$0.60$0.54291,195 shs$49.48 million06/04/2025$0.58$0.58-1.15%$0.60$0.5298,639 shs$51.61 million06/03/2025$0.59$0.58-1.02%$0.63$0.53402,221 shs$52.21 million06/02/2025$0.59$0.59+0.34%$0.63$0.52232,566 shs$52.75 million05/30/2025$0.62$0.59-5.06%$0.66$0.491.04 million shs$52.57 million05/29/2025$0.64$0.62-3.98%$0.71$0.50907,047 shs$55.37 million Get the Latest News and Ratings for CNTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/28/2025$0.68$0.64-5.60%$0.70$0.6463,791 shs$57.66 million05/27/2025$0.69$0.68-1.73%$0.71$0.6761,948 shs$61.08 million05/26/2025$0.69$0.69$0.71$0.6678,969 shs$62.16 million05/23/2025$0.71$0.69-1.77%$0.71$0.6678,969 shs$62.16 million05/22/2025$0.69$0.71+2.08%$0.72$0.6920,923 shs$63.28 million05/21/2025$0.68$0.69+1.80%$0.72$0.6745,184 shs$61.99 million05/20/2025$0.71$0.68-3.89%$0.73$0.66177,934 shs$60.89 million05/19/2025$0.71$0.71-0.77%$0.75$0.7075,530 shs$63.36 million05/16/2025$0.75$0.71-5.09%$0.79$0.70102,223 shs$63.85 million05/15/2025$0.79$0.75-5.06%$0.79$0.7266,349 shs$67.28 million05/14/2025$0.82$0.79-3.66%$0.85$0.7779,300 shs$70.87 million05/13/2025$0.78$0.82+5.14%$0.85$0.77143,109 shs$73.56 million05/12/2025$0.76$0.78+2.42%$0.83$0.74104,441 shs$69.96 million Related Companies AVTE Stock Price Chart YMAB Stock Price Chart ACTU Stock Price Chart ENGN Stock Price Chart SCPH Stock Price Chart CTMX Stock Price Chart DRUG Stock Price Chart CRGX Stock Price Chart IPHA Stock Price Chart NBTX Stock Price Chart Receive CNTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:CNTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTX Stock Free CNTX Stock Alerts